CLOS
ALXN

Compagnie Lombard Odier SCmA’s Alexion Pharmaceuticals ALXN Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,900
Closed -$296K – 696
2020
Q4 		$296K Buy
1,900
+1,872
+6,686% +$241K 0.01% 290
2020
Q3 		$3K Buy
+28
New +$3.02K ﹤0.01% 512
2019
Q1 		– Sell
-1,400
Closed -$174K – 617
2018
Q4 		$136K Sell
1,400
-3,230
-70% -$382K 0.01% 304
2018
Q3 		$644K Hold
4,630
– – 0.02% 179
2018
Q2 		$575K Hold
4,630
– – 0.02% 196
2018
Q1 		$516K Sell
4,630
-2,230
-33% -$267K 0.02% 218
2017
Q4 		$820K Buy
6,860
+3,430
+100% +$418K 0.01% 250
2017
Q3 		$481K Hold
3,430
– – 0.02% 271
2017
Q2 		$417K Hold
3,430
– – 0.01% 292
2017
Q1 		$416K Sell
3,430
-1,100
-24% -$142K 0.01% 301
2016
Q4 		$555K Sell
4,530
-1,400
-24% -$171K 0.02% 319
2016
Q3 		$727K Hold
5,930
– – 0.02% 309
2016
Q2 		$693K Hold
5,930
– – 0.02% 305
2016
Q1 		$825K Sell
5,930
-1,360
-19% -$200K 0.03% 276
2015
Q4 		$1.39M Sell
7,290
-140
-2% -$24.5K 0.04% 197
2015
Q3 		$1.16M Buy
7,430
+3,726
+101% +$680K 0.05% 185
2015
Q2 		$669K Sell
3,704
-756
-17% -$130K 0.02% 262
2015
Q1 		$773K Buy
4,460
+3,654
+453% +$661K 0.03% 256
2014
Q4 		$149K Sell
806
-444
-36% -$82.3K 0.01% 466
2014
Q3 		$208K Buy
1,250
+189
+18% +$31K 0.01% 496
2014
Q2 		$166K Hold
1,061
– – 0.01% 561
2014
Q1 		$161K Sell
1,061
-738
-41% -$117K 0.01% 569
2013
Q4 		$239K Buy
+1,799
New +$216K 0.01% 486

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ALXN Position: Q1 2021 in Review

Compagnie Lombard Odier SCmA sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,900 shares — an estimated $296K sold.

Compagnie Lombard Odier SCmA first reported a position in ALXN in Q4 2013 and held it in 23 quarters. The position peaked at $1.39M in Q4 2015. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1,900 Alexion Pharmaceuticals shares in Q1 2021, an estimated $296K.
  • Compagnie Lombard Odier SCmA first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 23 quarters.
  • Compagnie Lombard Odier SCmA's Alexion Pharmaceuticals position peaked at $1.39M in Q4 2015.
  • 752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2021, filed 23 Apr 2021.